This Week in General Medicine — Sep 14, 2026

Welcome to This Week in General Medicine. This week we're covering 10 notable papers spanning novel targeted therapies in stroke, haematology and lupus, bread-and-butter diagnosis and management in the clinic and emergency department, and a cluster of studies on prescribing safety, risk prediction and drug pricing. Let's dive in.

We start with three trials of genuinely new molecules. In JAMA, Li and colleagues report the LAIS trial, a phase 3, double-blind, placebo-controlled study of loberamisal, an intravenous small molecule that targets both the postsynaptic density 95 pathway and the alpha-2 GABA-A receptor, across 32 hospitals in China [1]. Just under a thousand adults with acute ischaemic stroke, a baseline National Institutes of Health Stroke Scale score between 7 and 20 and no prestroke disability were randomised within 48 hours of onset to ten daily infusions or placebo on top of standard care. At 90 days, the proportion achieving a full functional outcome — a modified Rankin score of zero or one — was about 13 percentage points higher with the drug, reaching just under 70 percent compared with roughly 56 percent on placebo, with no excess of adverse events, serious adverse events or deaths. That is a large effect for a neuroprotectant, a class littered with failures, and it deserves the caution the authors themselves apply: a single country, a relatively mild-to-moderate median stroke severity with a median baseline score of 8, and an enrolment period of under five months. This is not yet a change in practice, but it is a trial to watch for replication outside China.

Staying with new drugs, The Lancet published ENERGIZE-T, a global phase 3 trial of mitapivat, an oral allosteric activator of pyruvate kinase, in 258 adults with transfusion-dependent alpha- or beta-thalassaemia, led by Cappellini and colleagues [2]. Patients were randomised two to one to 100 milligrams twice daily or placebo for 48 weeks. The primary endpoint, a transfusion reduction response of at least fifty percent fewer red cell units over a consecutive twelve-week window, was met by about 30 percent of patients on mitapivat versus roughly 13 percent on placebo, an absolute gain of around 18 percentage points. Headache, upper respiratory infection, insomnia, diarrhoea and fatigue were the commonest adverse events, serious adverse events were no more frequent than with placebo, and there were no deaths. For a disease where alpha-thalassaemia has had no disease-modifying therapy at all, an oral option that reduces transfusion burden in a meaningful minority of patients is a real addition — but note that most patients did not respond, so expectation-setting matters. And in Nature Medicine, Xu and colleagues report the intravenous arm of a first-in-disease phase 1 trial of A-319, a CD3-by-CD19 bispecific T cell engager, in 12 patients with active systemic lupus erythematosus followed for a year [3]. The primary endpoint was safety, and it was reassuring: no treatment-related serious adverse events, no deaths, no high-grade cytokine release syndrome or neurotoxicity, with cytokine release almost entirely grade 1. Among exploratory efficacy endpoints, eight of ten evaluable patients reached a low disease activity state and six of ten met remission criteria at twelve months, with deep peripheral B cell depletion and immune reprogramming resembling that seen after CD19 CAR T therapy. The appeal here is an off-the-shelf product with no lymphodepletion and no cell manufacturing — but this is twelve patients, uncontrolled efficacy, and pivotal trials are the next step.

The second theme is the everyday diagnostic and management work of general medicine, covered this week by three substantial reviews. Smolen and colleagues review rheumatoid arthritis in adults in JAMA, and the message for the generalist is the front end of the pathway [4]. Rheumatoid arthritis affects around half a percent of adults worldwide, is twice as common in women, and peaks between ages 55 and 75. There are no formal diagnostic criteria, so diagnosis rests on the history, characteristic swelling of proximal interphalangeal, metacarpophalangeal and wrist joints, C-reactive protein, and autoantibodies — which, importantly, are absent in a substantial share of patients at diagnosis, so a negative rheumatoid factor and negative anti-citrullinated peptide antibody do not exclude the disease. The target is diagnosis ideally within six weeks of symptom onset, methotrexate started at 7.5 to 10 milligrams weekly and escalated to 20 to 25 milligrams within four to eight weeks, with short-course glucocorticoids tapered off within three months. Roughly 40 percent of newly diagnosed patients reach remission on that first-line strategy; adding a biological agent or a Janus kinase inhibitor lifts remission or low disease activity to around 80 percent, with the caveat that Janus kinase inhibitors should be avoided in patients at high thromboembolic, cardiovascular or malignancy risk. In the BMJ, Long and colleagues review skin and soft tissue infections, and the practical points are the division into non-purulent disease, usually beta-haemolytic streptococcal, and purulent disease, usually staphylococcal; the limited value of laboratory testing in most patients; and point-of-care ultrasound as the tool of choice when you cannot tell cellulitis from abscess [5]. Abscess needs incision and drainage, with antibiotics reserved for selected patients, and decolonisation for recurrent disease remains genuinely controversial. Rounding out the group, Nature Reviews Disease Primers offers a primer on toxidromes from Roberts and colleagues, a reminder that pattern recognition across the opioid, sympathomimetic, serotonergic, antimuscarinic, muscarinic and nicotinic syndromes is often the only diagnostic route available when the patient is too drowsy or too agitated to give a history [6].

The third theme is prescribing safety, risk prediction and the health system around them. The standout is a BMJ population-level retrospective cohort from Rochon and colleagues examining potentially inappropriate prescribing cascades in nearly 2.3 million community-dwelling older adults in Ontario [7]. Starting from 65 cascades identified by international expert consensus, they applied thresholds for how common the initial drug is, how often the pairing occurs, and whether the second drug genuinely follows the first in time — and 24 cascades, a little over a third of them, met all three criteria. Cardiovascular drugs were the most common initiators. The highest-incidence sequences were iron supplement to laxative, at about one in eight patients; statin to analgesic, at around one in nine; and cholinesterase inhibitor to sleep agent, at roughly one in ten. The strongest temporal signals were corticosteroid followed by antipsychotic and laxative followed by antidiarrhoeal, each around two and a half times more likely in that order than the reverse. That is a concrete, prioritised checklist for medication review: when a new drug appears, ask whether it is treating a side effect of an old one. Alongside it, also in the BMJ, Liang and colleagues directly tested whether cardiovascular risk equations travel, deriving parallel five-year equations in roughly 48,000 New Zealanders and 47,000 Chinese primary prevention patients with diabetes [8]. Most predictor effects were similar, but age behaved very differently — in women, each additional decade carried substantially more risk in the Chinese cohort than in the New Zealand one. Standard recalibration of the New Zealand equation did not fix its performance in China; replacing the age coefficient did. The lesson is that importing a risk calculator from a high-income setting and simply rescaling it can mislead. And in The Lancet, Hwang and colleagues modelled the Centers for Medicare and Medicaid Services most-favoured-nation payment models across 195 brand-name drugs accounting for nearly 88 billion dollars of Medicare spending, projecting reductions of roughly 16 to 18 percent — but with savings falling by about seventy percent if manufacturers with separate government agreements are exempted [9]. Finally, Nature Medicine reports a French national cohort of over 95,000 adults starting immune checkpoint inhibitors, where messenger RNA COVID-19 vaccination around the time of initiation was associated with modestly lower mortality in the first three to six months and no significant association by twelve months [10]. Because similar early patterns appeared with non-messenger RNA and unrelated adult vaccines, Salem and colleagues interpret this as a transient or healthy-vaccinee effect rather than a specific immunological interaction — reassuring for vaccinating patients on checkpoint inhibitors, but not evidence that vaccination boosts cancer therapy.

If you only have time for one paper this week, make it the BMJ prescribing cascade cohort [7]. It converts a familiar geriatric principle into a ranked, twenty-four-item list you can apply at the next medication review, and unlike the trials above it requires no new drug, no new infrastructure and no waiting for replication.

Here are the key takeaways from this week in General Medicine. First, loberamisal produced a substantial functional benefit in acute ischaemic stroke within 48 hours in a Chinese phase 3 trial, but treat it as a signal awaiting external validation, not a new standard. Second, oral mitapivat modestly but significantly reduced transfusion burden in transfusion-dependent thalassaemia, the first oral disease-modifying option in this group, with a minority of patients responding. Third, a CD3-by-CD19 bispecific antibody achieved deep B cell depletion in lupus without lymphodepletion and with only low-grade cytokine release, in twelve patients. Fourth, in rheumatoid arthritis, act fast — diagnose within six weeks, escalate methotrexate within eight, and remember that negative autoantibodies do not rule it out. And fifth, when a new prescription appears in an older adult's list, ask whether it is treating a side effect, and be sceptical about applying imported cardiovascular risk equations without updating the age term.

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.